- Morphic Therapeutic (NASDAQ:MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD).
- The data were shared at the Congress of European Crohn’s and Colitis Organization 2021 Virtual Congress.
- The additional data include detail regarding the safety, pharmacokinetics (PK), and pharmacodynamics (PD) performance of MORF-057 in healthy subjects.
- MORF-057 was well tolerated in all cohorts, and no safety signals were identified. It demonstrated a favorable PK profile, and an apparent PK and PD relationship were established.
- α4β7 receptor occupancy increased with dose and study day, achieving saturation in patients from all cohorts above 25 mg by day 14.
- In the 100 mg BID cohort, MORF-057 saturated the α4β7 receptor (mean RO more than 99%).
- Dose-and time-dependent changes in biomarkers, including specific α4β7 high expressing immune cell populations, were observed.
- The company held a conference call today at 8:00 AM ET.
- Price Action: MORF shares are up 3.16% at $59.43 on the last check Friday.
Needham Maintains Buy on HubSpot, Raises Price Target to $470
Needham analyst Joshua Reilly maintains HubSpot (NYSE:HUBS) with a Buy and raises the price target from $380 to $470.
